The N6‐methyladenosine (m6A) RNA modification has gained significant prominence as a new layer of regulatory mechanism that governs gene expression. Over the past decade, various m6A regulators responsible for introducing, eliminating, and recognising RNA methylation have been identified. Notably, these m6A regulators often exhibit altered expression patterns in cancer, occasionally offering prognostic value. Nonetheless, the complex roles of these regulators in human cancer pathology remain enigmatic, with conflicting outcomes reported in different studies.In recent years, a multitude of inhibitors and activators targeting m6A regulators have been reported. Several of these compounds have demonstrated promising efficacy in both in vitro and in vivo cancer models. These findings collectively underscore the dynamic landscape of m6A regulation in cancer biology, revealing its potential as a therapeutic target and prognostic indicator.

中文翻译：

---

用药物靶向 RNA 修饰：癌症治疗的新领域

N6-甲基腺苷 (m6A) RNA 修饰作为控制基因表达的新一层调控机制已获得显着的关注。在过去的十年中，已经确定了负责引入、消除和识别 RNA 甲基化的各种 m6A 调节因子。值得注意的是，这些 m6A 调节因子在癌症中经常表现出改变的表达模式，偶尔提供预后价值。尽管如此，这些调节因子在人类癌症病理学中的复杂作用仍然是个谜，不同的研究报告的结果相互矛盾。近年来，已经报道了多种针对 m6A 调节因子的抑制剂和激活剂。其中几种化合物已在体外和体内癌症模型中表现出良好的功效。这些发现共同强调了 m6A 调控在癌症生物学中的动态格局，揭示了其作为治疗靶点和预后指标的潜力。